Italian Advisory Board: sFlt-1/PlGF ratio and preeclampsia, state of the art and developments in diagnostic, therapeutic and clinical management

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 206, Issue , 2016, Pages 70-73

  Di Martino, Daniela ^a   Cetin, Irene ^a   Frusca, Tiziana ^b   Ferrazzi, Enrico ^a   Fuse’, Federica ^a   Gervasi, Maria Teresa ^c   Plebani, Mario ^c   Todros, Tullia ^d  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

Angiogenic markers; Placenta; Preeclampsia

Indexed keywords

PLACENTAL GROWTH FACTOR; SOLUBLE FMS LIKE TYROSINE KINASE RECEPTOR 1; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; FLT1 PROTEIN, HUMAN; PGF PROTEIN, HUMAN;

ADVERSE OUTCOME; ARTICLE; DISEASE SEVERITY; EMERGENCY HEALTH SERVICE; FEMALE; FETUS OUTCOME; FIRST TRIMESTER PREGNANCY; HUMAN; ITALY; MATERNAL HYPERTENSION; MATERNAL OUTCOME; PARAMETERS CONCERNING THE FETUS, NEWBORN AND PREGNANCY; PREDICTION; PREECLAMPSIA; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; ADULT; BLOOD; PRACTICE GUIDELINE; PRE-ECLAMPSIA; PREGNANCY;

ADULT; FEMALE; HUMANS; ITALY; PLACENTA GROWTH FACTOR; PRE-ECLAMPSIA; PREGNANCY; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84988038857     PISSN: 03012115     EISSN: 18727654     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2016.08.036     Document Type: Article

References (40)

1. [1] Steegers, E.A., von Dadelszen, P., Duvekot, J., et al. Pre-eclampsia. Lancet 376 (2010), 631–644.
2. [2] Redman, C.W., Sargent, I.L., Staff, A.C., IFPA Senior Award Lecture: making sense of pre-eclampsia. Placenta 35 (2014), S20–S25.
3. [3] Borzychowski, A.M., Sargent, I.L., Redman, C.W., Inflammation and pre-eclampsia. Semin Fetal Neonatal Med 11 (2006), 309–316.
4. [4] Yung, H., Calabrese, S., Hynx, D., et al. Evidence of placental translation inhibition and endoplasmic reticulum stress in the etiology of human intrauterine growth restriction. Am J Pathol 173 (2008), 451–462.
5. [5] Cardaropoli, S., Paulesu, L., Romagnoli, R., et al. Macrophage migration inhibitory factor in fetoplacental tissues from preeclamptic pregnancies with or without fetal growth restriction. Clin Dev Immunol, 2012, 2012, 639342.
6. [6] Rolfo, A., Giuffrida, D., Nuzzo, A.M., et al. Pro-inflammatory profile of preeclamptic placental mesenchymal stromal cells: new insights into the etiopathogenesis of preeclampsia. PLoS One, 8(3), 2013, e59403.
7. [7] Orabona, R., Donzelli, C.M., Falchetti, M., Santoro, A., Valcamonico, A., Frusca, T., Placental histological patterns and uterine artery Doppler velocimetry in pregnancies complicated by early or late preeclampsia. Ultrasound Obstet Gynecol 47:5 (2016 May), 580–585.
8. [8] Staff, A.C., Redman, C.W.G., IFPA Award in Placentology Lecture: preeclampsia, the decidual battleground and future maternal cardiovascular disease. Placenta 35 (2014), S26–S31.
9. [9] Valensise, H., Vasapollo, B., Gagliardi, G., Novelli, G.P., Early and late preeclampsia: two different maternal hemodynamic states in the latent phase of the disease. Hypertension 52:October (5) (2008), 873–880.
10. [10] Melchiorre, K., Sharma, R., Thilaganathan, B., Cardiovascular implications in preeclampsia: an overview. Circulation 130:August (8) (2014), 703–714.
11. [11] Orabona, R., Vizzardi, E., Sciatti, E., et al. Insights into cardiac alterations after preeclampsia: an echocardiographic study. Ultrasound Obstet Gynecol, 2016, 10.1002/uog.15983.
12. [12] National Collaborating Centre for Women's and Children's Health (UK). NICE Clinical Guidelines, n° 107. Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. London: RCOG Press; 2010.
13. [13] WHO Guidelines approved by the Guidelines Review Commettee. WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. Geneva: World Health Organization; 2011.
14. [14] American College of Obstetricians and Gynecologists. Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013;122:1122–31.
15. [15] Ferrazzi, E., Zullino, S., Stampalija, T., et al. Bedside diagnosis of two major clinical phenotypes of hypertensive disorders of pregnancy. Ultrasound Obstet Gynecol, 2015, 10.1002/uog.15741.
16. [16] Espinoza, J., Kusanovic, J.P., Bahado-Singh, R., et al. Should bilateral uterine artery notching be used in the risk assessment for preeclampsia, small for gestational age and gestational hypertension. J Ultrasound Med, 29(October (10)), 2010, 1494.
17. [17] Lowe, S.A., Brown, M.A., Dekker, G.A., et al. For the Society of Obstetric Medicine of Australia and New Zealand. Guidelines for the management of hypertensive disorders of pregnancy 2008. Aust N Z J Obstet Gynaecol Can, 2008.
18. [18] Magee, L.A., Pels, A., Helewa, M., et al. Diagnosis, evaluation and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can 36 (2014), 575–576.
19. [19] Conde-Agudelo, A., Belizan, J.M., Risk factors for pre-eclampsia in a large cohort of Latin American and Carribean women. BJOG 107:January (1) (2000), 75–83.
20. [20] Lozano, R., Naghavi, M., Foreman, K., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:December (9859) (2012), 2095–2128.
21. [21] Cetin, I., Huppertz, B., Burton, G., et al. Pregenesys pre-eclampsia markers consensus meeting: what do we require from markers, risk assessment and model systems to tailor preventive strategies?. Placenta 22 (2010), 1–13.
22. [22] Karumanchi, S.A., Epstein, S.H., Placental ischemia and soluble fms-like tyrosine kinase 1: cause or consequence of preeclampsia. Kidney Int 71 (2007), 959–961.
23. [23] Kendall, R.L., Thomas, K.A., Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A 90 (1993), 10705–10709.
24. [24] Lu, F.X., Longo, M., Tamayo, E., et al. The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. Am J Obstet Gynecol, 196(4), 2007, 396 e1-7.
25. [25] Verlohren, S., Galindo, A., Schlembach, D., et al. An automated method for the determination of the sFlt-1/PlGF ratio in the assessment of preeclampsia. AJOG, 2010, 10.1016/j.ajog.2009.09.016.
26. [26] Verlohren, S., Herraiz, I., Lapaire, O., et al. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension 63 (2014), 346–352.
27. [27] German guideline. Available at: http://www.awmf.org/uploads/tx_szleitlinien/015-018l_S1_Diagnostik_Therapie_hypertensiver_Schwangerschaftserkrankungen_2014-01.pdf.
28. [28] Levine, R.J., Maynard, S.E., Qian, C., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl Med 350 (2004), 672–683.
29. [29] Levine, R.J., Liam, C., Qian, C., et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl Med, 2006 355-992-10005.
30. [30] Zeisler, H., Llurba, E., Chantraine, F., et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med 374:1 (2016), 13–22.
31. [31] Cetin, I., Mazzocco, M.I., Giardini, V., et al. PlGF in a clinical setting of pregnancies at risk of preeclampsia and/or intrauterine growth restriction. J Matern Fetal Neonatal Med 19 (2016), 1–6.
32. [32] Hund, M., Allegranza, D., Schoedi, M., Dilba, P., Verhagen-Kamerbeek, W., Stepan, H., Multicenter prospective clinical study to evaluate the prediction of short-term outcome in pregnant women with suspected preeclampsia (PROGNOSIS): study protocol. BMC Pregnancy Childbirth 18 (2014), 14–324.
33. [33] Espinoza, J., Romero, R., Nien, J.K., et al. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol 196:326 (2007), e1–13.
34. [34] Stepan, H., Unversucht, A., Wessel, N., Faber, R., Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 49 (2007), 818–824.
35. [35] Diguisto, C., Le Gouge, A., Piver, E., Giraudeau, B., Peerotin, F., Second-trimester uterine artery Doppler, PlGF, sFlt-1, sEndoglin, and lipid-related markers for predicting preeclampsia in a high-risk population. Prenat Diagn 33 (2014), 1070–1074.
36. [36] Stubert, J., Ullmann, S., Bolz, M., et al. Prediction of preeclampsia and induced delivery at <34 weeks gestation by sFlt-1 and PlGF in patients with abnormal midtrimester uterine Doppler velocimetry: a prospective cohort analysis. BMC Pregnancy Childbirth, 14, 2014, 292.
37. [37] Henderson, J.T., Whitlock, E.P., O'Connor, E., Senger, C.A., Thompson, J.H., Rowland, M.G., Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Service Task Force. Ann Intern Med 160 (2014), 695–703.
38. [38] Stepan, H., Herraiz, I., Schlembach, D., et al. Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice. Ultrasound Obstet Gynecol 45:3 (2015), 241–246.
39. [39] Alvarez-Fernandez, I., Prieto, B., Rodriguez, V., Ruano, Y., Escudero, A.I., Alvarez, F.V., New biomarkers in diagnosis of early onset preeclampsia and imminent delivery prognosis. Clin Chem Lab Med 52 (2014), 1159–1168.
40. [40] Chappell, L.C., Duckworth, S., Seed, P.T., et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation 128 (2013), 2121–2131.